RNTX
RNTX
NASDAQ · Biotechnology

Rein Therapeutics Inc

$1.14
+0.00 (+0.00%)
As of Feb 8, 2:22 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 47.89M 42.94M 46.10M
Net Income 949.8K 770.7K 699.4K
EPS
Profit Margin 2.0% 1.8% 1.5%
Rev Growth -0.9% +8.9% +4.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 5.62M 6.92M 6.69M
Total Equity 16.94M 17.73M 15.71M
D/E Ratio 0.33 0.39 0.43
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 1.44M 1.43M 1.37M
Free Cash Flow 717.1K 500.4K 604.2K